Regenexx, LLC

Founded in 2005 by Dr. Chris Centeno and Dr. John Schultz, Regenexx pioneered the field of interventional orthopedics, a non-surgical approach to treating musculoskeletal (MSK) conditions using the body's own biology, specifically bone marrow concentrate and platelet-rich plasma.
The Regenexx Corporate Program packages this clinical innovation as a no PEPM employee benefit for self-funded employers, helping them reduce MSK spend by up t0 70% and total medical spend by up to 10%. With 3,500+ active employer clients, 2.5 million covered lives, the program has a proven track record backed by a 95%+ client retention rate since 2015.
The clinical network spans across the U.S with 200+ board-certified physicians, supported by proprietary technology and image-guided injection protocols. Regenexx has published 46+ peer-reviewed studies and roughly half of all worldwide research on bone marrow concentrate for orthopedic injuries.
The program integrates seamlessly with existing health plans through partnerships with 125+ TPAs and ~100 stop-loss carriers, with onboarding in as little as two weeks at zero cost to the plan.